Advertisement
-- 48th Annual ICAAC/IDSA Annual Meeting in Washington D.C. fromOctober 25 through October 28. Advanced Life Sciences will present clinicaland microbiology data in posters and an oral presentation pertaining to itslead respiratory antibiotic cethromycin. The Company will also sponsor a"Meet the Experts" series focused on respiratory tract pathogens and bacterialresistance led by infectious disease physicians Dr. Thomas File and Dr. DonaldLow during the conference.
Advertisement
-- Rodman & Renshaw Annual Global Investment Conference in New York Cityon Wednesday, November 12, 2008 at 2:50PM ET.
-- Lazard Capital Markets 5th Annual Healthcare Conference in New YorkCity on Tuesday, November 18, 2008 at 1:10PM ET.
A live webcast will be available for each of the investor conferences, andmay be accessed under "Event Calendar" on the Investors section of AdvancedLife Sciences website at www.advancedlifesciences.com.
-- Third Quarter Earnings Conference Call to be webcast live over theinternet on November 6th at 10:00AM ET. To access the webcast, visit theInvestor Relations section of the Advanced Life Sciences corporate website atwww.advancedlifesciences.com. Alternatively, investors may participate in theconference call by dialing 888-680-0893 (domestic) or 617-213-4859(international). The passcode for the conference call is 80103777. A replayof the conference call will be available until November 13, 2008. Callers mayaccess the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888(international), passcode 96626416. Investors are advised to dial into thecall at least ten minutes prior to the call to register. Participants maypre-register for the call athttps://www.theconferencingservice.com/prereg/key.process?key=PN3D7M9E4.Pre-registrants will be issued a pin number to use when dialing into the livecall which will provide quick access to the conference by bypassing theoperator upon connection.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in thediscovery, development and commercialization of novel drugs in the therapeuticareas of infection, cancer and respiratory diseases. The Company's leadcandidate, cethromycin, is a novel NDA-stage once-a-day oral antibiotic forthe treatment of respiratory tract infections including community acquiredpneumonia. For more information, please visit us on the web atwww.advancedlifesciences.com.
Any statements contained in this press release that relate to futureplans, events or performance are forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Theseforward-looking statements are subject to a number of risks and uncertaintiesthat could cause actual results to differ materially from those described inthe forward-looking statements. These risks and uncertainties include, amongothers, those relating to technology and product development, marketacceptance, government regulation and regulatory approval processes,intellectual property rights and litigation, dependence on collaborativerelationships, ability to obtain financing, competitive products, industrytrends and other risks identified in Advanced Life Sciences' filings with theSecurities and Exchange Commission. Advanced Life Sciences undertakes noobligation to update or alter these forward-looking statements as a result ofnew information, future events or otherwise.Company Contact: Joe Camp 630-754-4352 Email: [email protected] Media Contact: Melanie Nimrodi, Financial Relations Board, 312-546-3508 Email: [email protected] Investors Contact: Kathy Price, Financial Relations Board, 213-486-6547 Email: [email protected]
SOURCE Advanced Life Sciences Holdings, Inc.
